Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1982 Jul;37(1):264–270. doi: 10.1128/iai.37.1.264-270.1982

Protection against group B Neisseria meningitidis disease: effect of serogroup B polysaccharide and polymyxin B on immunogenicity of serotype protein preparations.

M S Peppler, C E Frasch
PMCID: PMC347522  PMID: 6809628

Abstract

The inability to prepare an effective polysaccharide vaccine against group B Neisseria meningitidis was the impetus for these studies. Outer membrane protein vaccines used in our initial studies failed to induce bactericidal antibodies in humans. The particulate nature of these vaccines may have led to their clearance before effective immune stimulation. Less denaturing procedures, therefore, were developed for preparation of serotype 2 protein-containing vaccines. These procedures included isolation of naturally released outer membrane vesicles and selective removal of lipopolysaccharide from the vesicles by the nonionic detergent Brij-96. The resultant protein vaccines were evaluated with and without noncovalently complexed group B meningococcal polysaccharide or polymyxin B sulfate or both. The new vaccines were at least 10-fold more immunogenic in mice and guinea pigs than the previous vaccines when assayed for bactericidal and enzyme-linked immunosorbent assay antibodies. The protein vaccines alone protected guinea pigs from intrachamber infection, and a single 0.1-microgram injection prevented meningococcal bacteremia in mice. Addition of group B polysaccharide to the protein significantly improved the immunogenicity of the protein, and this combined vaccine showed a greater protective effect. Polymyxin B generally reduced the immunogenicity of the vaccines in both mice and guinea pigs.

Full text

PDF
264

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Corrigan J. J., Jr, Kiernat J. F. Effect of polymyxin B sulfate on endotoxin activity in a gram-negative septicemia model. Pediatr Res. 1979 Jan;13(1):48–51. doi: 10.1203/00006450-197901000-00011. [DOI] [PubMed] [Google Scholar]
  2. Craven D. E., Frasch C. E. Protection against group B meningococcal disease: evaluation of serotype 2 protein vaccines in a mouse bacteremia model. Infect Immun. 1979 Oct;26(1):110–117. doi: 10.1128/iai.26.1.110-117.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Frasch C. E., Chapman S. S. Classification of Neisseria meningitidis group B into distinct serotypes. 3. Application of a new bactericidal-inhibition technique to distribution of serotypes among cases and carriers. J Infect Dis. 1973 Feb;127(2):149–154. doi: 10.1093/infdis/127.2.149. [DOI] [PubMed] [Google Scholar]
  4. Frasch C. E., Chapman S. S. Classification of Neisseria meningitidis group B into distinct serotypes. I. Serological typing by a microbactericidal method. Infect Immun. 1972 Jan;5(1):98–102. doi: 10.1128/iai.5.1.98-102.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Frasch C. E., Gotschlich E. C. An outer membrane protein of Neisseria meningitidis group B responsible for serotype specificity. J Exp Med. 1974 Jul 1;140(1):87–104. doi: 10.1084/jem.140.1.87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Frasch C. E., Parkes L., McNelis R. M., Gotschlich E. C. Protection against group B meningococcal disease. I. Comparison of group-specific and type-specific protection in the chick embryo model. J Exp Med. 1976 Aug 1;144(2):319–329. doi: 10.1084/jem.144.2.319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Frasch C. E., Peppler M. S. Protection against group B Neisseria meningitidis disease: preparation of soluble protein and protein-polysaccharide immunogens. Infect Immun. 1982 Jul;37(1):271–280. doi: 10.1128/iai.37.1.271-280.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Frasch C. E., Robbins J. D. Protection against group B meningococcal disease. II. Infection and resulting immunity in a guinea pig model. J Exp Med. 1978 Mar 1;147(3):619–628. doi: 10.1084/jem.147.3.619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Frasch C. E., Robbins J. D. Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model. J Exp Med. 1978 Mar 1;147(3):629–644. doi: 10.1084/jem.147.3.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gruninger R. P., Howe C. W. Temporal protection of chick embryo against endotoxin by isoproterenol, polymyxin B sulfate, and hydrocortisone. Proc Soc Exp Biol Med. 1969 Apr;130(4):1202–1205. doi: 10.3181/00379727-130-33754. [DOI] [PubMed] [Google Scholar]
  11. Helting T. B., Guthöhrlein G., Blackkolb F., Ronneberger H. Serotype determinant protein of Neisseria Meningitidis. Large scale preparation by direct detergent treatment of the bacterial cells. Acta Pathol Microbiol Scand C. 1981 Apr;89(2):69–78. [PubMed] [Google Scholar]
  12. Hochstein H. D., Elfin R. J., Cooper J. F., Seligmann E. B., Jr, Wolff S. M. Further developments of Limulus Amebocyte Lysate test. Bull Parenter Drug Assoc. 1973 May-Jun;27(3):139–148. [PubMed] [Google Scholar]
  13. Hoff G. E., Frasch C. E. Outer membrane antigens of Neisseria meningitidis group B serotype 2 studied by crossed immunoelectrophoresis. Infect Immun. 1979 Sep;25(3):849–856. doi: 10.1128/iai.25.3.849-856.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Huet M., Suire A. Mise en évidence de la valeur protectrice des vaccins poly-saccharidiques méningococciques par la réduction de la bactéríemie chez la Souris. C R Acad Sci Hebd Seances Acad Sci D. 1976 Sep 13;283(4):421–422. [PubMed] [Google Scholar]
  15. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  16. OSBORN M. J. STUDIES ON THE GRAM-NEGATIVE CELL WALL. I. EVIDENCE FOR THE ROLE OF 2-KETO- 3-DEOXYOCTONATE IN THE LIPOPOLYSACCHARIDE OF SALMONELLA TYPHIMURIUM. Proc Natl Acad Sci U S A. 1963 Sep;50:499–506. doi: 10.1073/pnas.50.3.499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Rifkind D., Palmer J. D. Neutralization of endotoxin toxicity in chick embryos by antibiotics. J Bacteriol. 1966 Oct;92(4):815–819. doi: 10.1128/jb.92.4.815-819.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Rifkind D. Prevention by polymyxin B of endotoxin lethality in mice. J Bacteriol. 1967 Apr;93(4):1463–1464. doi: 10.1128/jb.93.4.1463-1464.1967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Smith C. I., Hammarström L. B-cell activating properties of polymyxin B. Scand J Immunol. 1978;7(1):67–72. doi: 10.1111/j.1365-3083.1978.tb00427.x. [DOI] [PubMed] [Google Scholar]
  20. Tsai C. M., Frasch C. E. Chemical analysis of major outer membrane proteins of Neisseria meningitidis: comparison of serotypes 2 and 11. J Bacteriol. 1980 Jan;141(1):169–176. doi: 10.1128/jb.141.1.169-176.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Wyle F. A., Artenstein M. S., Brandt B. L., Tramont E. C., Kasper D. L., Altieri P. L., Berman S. L., Lowenthal J. P. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis. 1972 Nov;126(5):514–521. doi: 10.1093/infdis/126.5.514. [DOI] [PubMed] [Google Scholar]
  22. Zollinger W. D., Mandrell R. E., Altieri P., Berman S., Lowenthal J., Artenstein M. S. Safety and immunogenicity of a Neisseria meningitidis type 2 protein vaccine in animals and humans. J Infect Dis. 1978 Jun;137(6):728–739. doi: 10.1093/infdis/137.6.728. [DOI] [PubMed] [Google Scholar]
  23. Zollinger W. D., Mandrell R. E., Griffiss J. M., Altieri P., Berman S. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. J Clin Invest. 1979 May;63(5):836–848. doi: 10.1172/JCI109383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Zollinger W. D., Mandrell R. E. Outer-membrane protein and lipopolysaccharide serotyping of Neisseria meningitidis by inhibition of a solid-phase radioimmunoassay. Infect Immun. 1977 Nov;18(2):424–433. doi: 10.1128/iai.18.2.424-433.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES